Antolin Padilla, MD
Geriatric Medicine · Guaynabo, PRNPI 1235105495
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 33.1% of the total. Reporting peaked in 2020 at $1,084 and has fallen 88.5% since, to $124 in 2025. Among geriatric medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$896
- Sanofi-aventis U.S. LLC$489
- GSK$467
- Johnson & Johnson$462
- Eli Lilly Export S.A. Puerto Rico Branch$283
- plus $289 from 4 others
What the payments were for
- Food & beverage$4,15896%
- Education$1564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,428 |
| Boehringer Ingelheim | 45 | $896 |
| Sanofi-aventis U.S. LLC | 22 | $489 |
| GSK | 24 | $467 |
| Johnson & Johnson | 21 | $462 |
| Eli Lilly Export S.A. Puerto Rico Branch | 14 | $283 |
| PBG Puerto Rico LLC | 9 | $205 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Novo Nordisk | 1 | $20 |
| Abbott | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$4,314 in reported general payments places this provider in the 95th percentile of 76 geriatric medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $62,873 |
| FarxigaDapagliflozin Propanediol | 62 | $60,470 |
| TradjentaLinagliptin | 53 | $56,741 |
| Galantamine ErGalantamine Hbr | 268 | $53,268 |
| XareltoRivaroxaban | 58 | $52,669 |
| GlyxambiEmpagliflozin/Linagliptin | 46 | $48,603 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $47,064 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 46 | $44,064 |
| JardianceEmpagliflozin | 28 | $41,451 |
| SynthroidLevothyroxine Sodium | 216 | $24,231 |
| TrulicityDulaglutide | 22 | $21,716 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $15,971 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $15,866 |
| OzempicSemaglutide | 16 | $15,616 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $15,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Glyxambi, Trijardy Xr, Jardiance, Synjardy Xr | $896 | $219,080227 claims |
| AstraZenecaFarxiga, Brilinta | $1,428 | $66,40775 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $467 | $62,931106 claims |
| Johnson & JohnsonXarelto | $462 | $52,66958 claims |
| Novo NordiskOzempic | $20 | $15,61616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 geriatric medicine providers in Puerto Rico.
Other geriatric medicine in Guaynabo
- Daisy Baez FranceschiGuaynabo$2K
- Luis Tavarez GonzalezGuaynabo$250
- Ubaldo Santiago BuonoSan Juan$5K
- Ismael Toro GrajalesBayamon$5K
- Deric LopezManati$3K
- William Marrero OrtizSan Juan$3K
- Cristina Nevarez de JesusSan Juan$2K
- Natalie Rodriguez DesaldenToa Baja$2K
- Francisco Torres LozadaPonce$2K
- Carmen MarreroSan Juan$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.